$43.63
+1.44 (+3.41%)
Open$43.65
Previous Close$42.19
Day High$44.99
Day Low$43.00
52W High$71.50
52W Low$8.73
Volume—
Avg Volume1.78M
Market Cap3.15B
P/E Ratio—
EPS$-4.05
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
-59.9% upside
Current
$43.63
$43.63
Target
$17.51
$17.51
$11.65
$17.51 avg
$27.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 20.19M | 37.91M | 366.27M |
| Net Income | -249,538,925 | -421,597,583 | 43.81M |
| Profit Margin | -1,236.0% | -1,174.2% | 12.0% |
| EBITDA | -213,949,231 | -381,550,158 | 53.48M |
| Free Cash Flow | — | — | 19.66M |
| Rev Growth | -46.7% | -46.7% | -4.9% |
| Debt/Equity | 2.63 | 2.63 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |